Clinical Trial Update: MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of MEK inhibitor 162 in relapsed/refractory acute myeloid leukemia with poor prognosis; the study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• MEK inhibitor 162 (MEK inhibitor 162)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-04-20